BlossomHill Therapeutics, Inc. 3Q 2026: Net loss $(23.8)M, EPS $(8.75) — 10-Q Summary
BlossomHill Therapeutics reported a net loss of $23.8M for Q3 2026, widening from a $13.2M loss a year ago, with no revenue as it remains in clinical stages. The company is progressing with multiple clinical trials and expects IPO proceeds to fund operations into Q2 2028.
How this was made
The 30-second read
Why it matters
The Q3 loss underscores cash‑flow challenges but also signals ongoing trial activity and pipeline expansion.
Market read
Earnings release provides fresh data for traders assessing micro‑cap biotech risk/reward.
What to watch
Liquidity runway extends into Q2 2028, reducing immediate financing risk.
Background
BlossomHill Therapeutics is a clinical‑stage biopharma with no product revenue, funding operations through IPO proceeds.
Ticker impact
BlossomHill Therapeutics reported a Q3 2026 net loss of $23.8M and EPS of -$8.75, the first disclosure of these results.
Potential short‑term decline; watch for support around recent lows.
Earnings miss on a micro‑cap biotech typically triggers sell‑off, but upcoming IND filing in Q1 2027 may limit downside.
Market effects
Highlights continued cash burn in clinical‑stage biotech sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
The loss reflects heavy R&D investment; investors could view the pipeline progress as a catalyst.
Key entities
- companyBlossomHill Therapeutics, Inc.
Clinical‑stage biopharma reporting Q3 2026 results.